Sugi Predict

Sugi Predict / Compounds / SCHEMBL204814

SCHEMBL204814

SCHEMBL204814

CC(=O)Oc1cc(C)c(Br)c(C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.48
▸ ALDH1A1 P00352 4/20 0.46
▸ ACHE P22303 2/20 0.46
▸ MAPT P10636 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ TTR P02766 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GLA P06280 3/20 0.42
▸ GAA P10253 3/20 0.42
▸ HPGD P15428 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3925908 0.87 MAPT (0.42) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL203680 0.85 ALDH1A1 (0.43) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL23601757 0.85 ALOX5 (0.46) LMNAALDH1A1ACHEMAPTKDM4E
SCHEMBL25612185 0.84 LMNA (0.39) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL205239 0.82 CA2 (0.45) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL27788647 0.82 LMNA (0.38) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL6364662 0.82 LMNA (0.52) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL30786779 0.82 ALDH1A1 (0.50) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL3688841 0.80 LMNA (0.50) LMNAALDH1A1ACHEMAPTPOLB
SCHEMBL23809728 0.80 BACE1 (0.52) LMNAALDH1A1ACHEMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF Kynan Duke IP, LLC (US) 2023-05-25 — — US disclosed
CN-104870429-B Benzofuran derivative, preparation method therefor, and medical application thereof 四川海思科制药有限公司 2017-05-03 — — CN disclosed
CN-104870429-A Benzofuran derivative, preparation method therefor, and medical application thereof SICHUAN HAISCO PHARMACEUTICAL CO LTD 2015-08-26 — — CN disclosed
EP-2743268-A2 Fused cyclic compounds as GPR40 receptor modulators Takeda Pharmaceutical Company Limited (JP) 2014-06-18 — — EP disclosed
US-20140080891-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-20 — — US disclosed
US-20140080891-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-20 — — US disclosed
US-20140080891-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-20 — — US disclosed
EP-2248812-B1 FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS TAKEDA PHARMACEUTICAL (JP) 2013-12-25 — — EP disclosed
US-8598226-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-03 — — US disclosed
US-20130267589-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2013-10-10 — — US disclosed
US-20100197761-A1 Fused cyclic compounds YASUMA TSUNEO 2010-08-05 — — US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 — — US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 — — US disclosed
US-7732626-B2 Fused cyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-08 — — US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 — — US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 — — US disclosed
US-20100004312-A1 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 — — US disclosed
CN-101616913-A Fused ring compound TAKEDA PHARMACEUTICAL 2009-12-30 — — CN disclosed
EP-2041123-A2 FUSED CYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-01 — — EP disclosed
WO-2008001931-A2 FUSED CYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080891-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 LMNA 4399/4885ALDH1A1 3122/4885ACHE 4184/4885
US-20100004312-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 LMNA 4399/4885ALDH1A1 3122/4885ACHE 4184/4885
US-20130267589-A1 FUSED CYCLIC COMPOUNDS GPR119, GLP1R, GPR65 LMNA 4399/4885ALDH1A1 3122/4885ACHE 4184/4885
US-20230159421-A1 SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF CYP8B1, HSD11B1, HSD11B2 LMNA 636/4885ALDH1A1 288/4885ACHE 3406/4885
US-20100197761-A1 Fused cyclic compounds GPR119, GLP1R, GPR65 LMNA 4399/4885ALDH1A1 3122/4885ACHE 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.